Literature DB >> 3322911

The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion.

I R Jones1, D R Owens, A J Moody, S D Luzio, T Morris, T M Hayes.   

Abstract

The effects of porcine glucose-dependent insulinotropic polypeptide given by continuous intravenous infusion in normal subjects (n = 6) and Type 2 (non-insulin-dependent) diabetic patients (n = 6) have been investigated. The subjects were studied on 2 separate days after overnight fasts. On each day 25 g of glucose was infused from 0-30 min plus an infusion of either porcine glucose-dependent insulinotropic polypeptide (0.75 pmol . kg-1 . min-1) or control solution. During the glucose-dependent insulinotropic polypeptide infusion plasma glucose values were reduced in normal subjects from 30-60 min (p less than 0.01) and in Type 2 diabetic patients at 45 and 60 min (p less than 0.05). In the normal subjects insulin concentrations were greater from 10-35 min (p less than 0.01) following glucose-dependent insulinotropic polypeptide infusion and peak values were increased by 123%. In the Type 2 diabetic patients following glucose-dependent insulinotropic polypeptide infusion insulin levels were increased from 4-40 min (p less than 0.01) but peak values were only increased by 27%. In the normal subjects C-peptide values were greater from 25-45 min (p less than 0.01) following glucose-dependent insulinotropic polypeptide infusion and peak C-peptide levels were increased by 82%. In the Type 2 diabetic patients following the glucose-dependent insulinotropic polypeptide infusion C-peptide levels were increased from 6-55 min (p less than 0.01) and peak values were increased by 20%. Plasma glucose-dependent insulinotropic polypeptide levels were within the physiological post prandial range during the glucose-dependent insulinotropic polypeptide infusion.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3322911     DOI: 10.1007/BF00296993

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  27 in total

1.  Release of immunoreactive gastric inhibitory polypeptide (IR-GIP) by oral ingestion of food substances.

Authors:  I G Cleator; R H Gourlay
Journal:  Am J Surg       Date:  1975-08       Impact factor: 2.565

Review 2.  Identification and actions of gastric inhibitory polypeptide.

Authors:  J C Brown; J R Dryburgh; S A Ross; J Dupré
Journal:  Recent Prog Horm Res       Date:  1975

3.  Pancreatic alpha- and beta-cell responses to GIP infusion in normal man.

Authors:  D Elahi; D K Andersen; J C Brown; H T Debas; R J Hershcopf; G S Raizes; J D Tobin; R Andres
Journal:  Am J Physiol       Date:  1979-08

4.  Stimulation of insulin secretion by gastric inhibitory polypeptide in man.

Authors:  J Dupre; S A Ross; D Watson; J C Brown
Journal:  J Clin Endocrinol Metab       Date:  1973-11       Impact factor: 5.958

5.  Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics.

Authors:  T Krarup; S Madsbad; A J Moody; L Regeur; O K Faber; J J Holst; L Sestoft
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

6.  Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity.

Authors:  M Salera; P Giacomoni; L Pironi; G Cornia; M Capelli; A Marini; F Benfenati; M Miglioli; L Barbara
Journal:  J Clin Endocrinol Metab       Date:  1982-08       Impact factor: 5.958

7.  Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus.

Authors:  S A Ross; J C Brown; J Dupré
Journal:  Diabetes       Date:  1977-06       Impact factor: 9.461

8.  Functional GIP receptors in a hamster pancreatic beta cell line, In 111: specific binding and biological effects.

Authors:  B Amiranoff; N Vauclin-Jacques; M Laburthe
Journal:  Biochem Biophys Res Commun       Date:  1984-09-17       Impact factor: 3.575

9.  Metabolism of proinsulin, insulin, and C-peptide in the rat.

Authors:  A I Katz; A H Rubenstein
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

10.  Gastric inhibitory polypeptide hypersecretion in diabetes mellitus: effect of sulfonylurea treatment.

Authors:  J S Coxe; T M O'Dorisio; S Cataland; S E Crockett
Journal:  J Clin Endocrinol Metab       Date:  1981-05       Impact factor: 5.958

View more
  11 in total

1.  Insulin-regulated glucagon-like peptide-1 release from L cells: actin' out.

Authors:  Debbie C Thurmond
Journal:  Endocrinology       Date:  2009-12       Impact factor: 4.736

2.  Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.

Authors:  J J Meier; B Gallwitz; M Askenas; K Vollmer; C F Deacon; J J Holst; W E Schmidt; M A Nauck
Journal:  Diabetologia       Date:  2005-07-12       Impact factor: 10.122

3.  Comparative Intracerebroventricular and Intrathecal Administration of a Nanomolar Macrocyclic Melanocortin Receptor Agonist MDE6-5-2c (c[Pro-His-DPhe-Arg-Trp-Dap-Ala-DPro]) Decreases Food Intake in Mice.

Authors:  Danielle N Adank; Mary M Lunzer; Mark D Ericson; Zoe M Koeperich; Stacey L Wilber; Katlyn A Fleming; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2020-09-10       Impact factor: 4.418

Review 4.  Physiologic relevance of heterogeneity in the pancreatic beta-cell population.

Authors:  D Pipeleers; R Kiekens; Z Ling; A Wilikens; F Schuit
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

5.  The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  I R Jones; D R Owens; S Luzio; S Williams; T M Hayes
Journal:  Diabetologia       Date:  1989-09       Impact factor: 10.122

6.  High-fat feeding stimulates endocrine, glucose-dependent insulinotropic polypeptide (GIP)-expressing cell hyperplasia in the duodenum of Wistar rats.

Authors:  D Gniuli; A Calcagno; L Dalla Libera; R Calvani; L Leccesi; M E Caristo; R Vettor; M Castagneto; G Ghirlanda; G Mingrone
Journal:  Diabetologia       Date:  2010-06-30       Impact factor: 10.122

7.  Influence of hemodialysis on incretin hormones and insulin secretion in diabetic and non-diabetic patients.

Authors:  Anna Masajtis-Zagajewska; Ilona Kurnatowska; Małgorzata Wajdlich; Marta Jagodzińska; Michał Nowicki
Journal:  Int Urol Nephrol       Date:  2013-05-14       Impact factor: 2.370

8.  Beta-cell sensitivity to glucose is impaired after gastric bypass surgery.

Authors:  Marzieh Salehi; Amalia Gastaldelli; David A D'Alessio
Journal:  Diabetes Obes Metab       Date:  2017-12-18       Impact factor: 6.577

9.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Authors:  M A Nauck; M M Heimesaat; C Orskov; J J Holst; R Ebert; W Creutzfeldt
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

Review 10.  Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor.

Authors:  Francis S Willard; Kyle W Sloop
Journal:  Exp Diabetes Res       Date:  2012-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.